Peps
What is Cerebrolysin?
Cerebrolysin is a porcine-brain-derived mixture of peptides and amino acids. In CASTA, the confirmatory combined functional outcome after acute ischemic stroke was neutral.
Biological role or research focus
Neurological clinical research.
A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
Role reference: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. · 2012 ↗
Names you may encounter
Porcine brain peptide hydrolysate
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Peptide and amino-acid mixture; not one defined molecule
- Research focus
- Neurological clinical research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Biology & proposed mechanism
The mixture is studied for proposed neurobiological effects. A complex preparation cannot be represented by a single amino-acid sequence or atomic molecular structure.
Research context & identity
The selected study concerns adjunctive treatment after acute ischemic stroke, rather than enhancement of cognition in healthy people.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
CASTA acute ischemic stroke trial
What did this publication test, and what did it find?
- Population / model
- 1,070 patients with acute ischemic stroke.
- Study design
- Randomized placebo-controlled study of intravenous treatment alongside standard care, with 90-day follow-up.
- Main finding
- The confirmatory combined functional endpoint did not show a significant benefit. A post-hoc analysis suggested a signal in more severely affected participants.
- Limits & context
- A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
Human randomized trial · 2016
CARS · upper-limb recovery
What did the rehabilitation-focused trial find?
- Population / model
- Patients receiving early rehabilitation after stroke; 208 enrolled according to the publication’s full-text record.
- Study design
- Double-blind placebo comparison; 21-day treatment and standardized rehabilitation, beginning 24–72 hours after stroke. Primary outcome: Action Research Arm Test at day 90.
- Main finding
- The reported Mann–Whitney estimator for the arm-test outcome was 0.71 (95% CI 0.63–0.79), favoring Cerebrolysin. Premature discontinuation was 3.8%.
- How to read it
- A Mann–Whitney estimator of 0.71 is not a 71% cure or a 71% reduction in disability.
- Limits & context
- The authors called this exploratory and requested larger confirmation. Rehabilitation context and an arm-function endpoint differ from mortality outcomes. Read alongside CASTA and the evidence reviews rather than selecting only a favorable result.
Systematic review of randomized trials · 2023
Cochrane stroke review · 2023
What did the broader review conclude about death and serious harms?
- Population / model
- Seven eligible trials with 1,773 participants; the review included a related peptide mixture, Cortexin, as well as Cerebrolysin.
- Study design
- Searches through May–June 2022; independent extraction, risk-of-bias assessment, and GRADE evidence ratings.
- Main finding
- All-cause mortality RR was 0.96 (95% CI 0.65–1.41). For Cerebrolysin, non-fatal serious adverse events had RR 2.39 (95% CI 1.10–5.23), while total serious events did not clearly differ.
- How to read it
- Mortality, total serious events, and non-fatal serious events are separate endpoints.
- Limits & context
- Eligibility required treatment started within 48 hours. Missing functional-outcome reporting and risk-of-bias concerns restrict conclusions. The mortality pool contains a related agent; do not attribute every pooled result exclusively to Cerebrolysin.
Systematic review of randomized trials · 2025
Stroke meta-analysis · 2025
Does a newer favorable neurological-score result resolve the debate?
- Population / model
- 14 randomized trials totaling 2,884 patients with acute ischemic stroke.
- Study design
- Pooled neurological-score changes, functional independence, mortality, and harms; RoB 2 and GRADE assessments reported.
- Main finding
- The abstract reported improved neurological-score change, but functional independence was not statistically significant: RR 1.31 (95% CI 0.90–1.91). Mortality and total serious adverse events also did not clearly differ.
- How to read it
- A score change does not establish greater independence or survival.
- Limits & context
- Review eligibility and endpoint definitions differ from Cochrane. The abstract calls hemorrhagic-transformation results nonsignificant despite a confidence interval excluding 1; that inconsistency needs full-text and statistical review. It should not be used as settled evidence of safety or benefit.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Trial tolerability applies to the tested clinical preparation and setting. It does not verify a mixture sold under a similar name.
Evidence boundaries
A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
3 matching video records · 1 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Peptide Of The Week
Telehealth vs Research Peptides: The Truth Nobody Tells You | Peptide of the Week Q&A #61 ↗
Captions indexed · Automatic matches need review
Biohackingturkey
Cerebrolysin Nedir? Beyin Hücrelerini Yenileyen Mucize mi? ↗
Title match · Captions not indexed
Dr. Trevor Bachmeyer
Cerebrolysin Can Repair The Brain - Dr Trevor Bachmeyer ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Can Cerebrolysin have one exact molecular diagram?
- What material, population, and route were actually studied?
- A subgroup signal following a neutral primary result needs confirmation; it should not be substituted for the main trial outcome.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can Cerebrolysin have one exact molecular diagram?
No. It is a mixture, so a single atomic drawing would misrepresent the preparation.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
- PubMed · PMID 22282884 ↗
- CARS · upper-limb recovery · 2016 ↗
- Cochrane stroke review · 2023 · 2023 ↗
- Stroke meta-analysis · 2025 · 2025 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.